{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:14:07Z","timestamp":1793826847698,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001862","name":"The Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thur\u00e9us foundation"},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005784","name":"Dalarna University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010949","name":"Copenhagen Trial Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"The Danish Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Copenhagen Hospital Corporation"},{"name":"The Danish Research Council"},{"name":"The 1991 Pharmacy Foundation"},{"name":"The Copenhagen Trial Unit"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.atherosclerosis.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:24:14Z","timestamp":1537057454000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5813-5926","authenticated-orcid":false,"given":"Jonas","family":"Wuopio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Bring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Sajadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorm Boje","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Kj\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00f8rn","family":"Kolmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Winkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6113-0472","authenticated-orcid":false,"given":"Axel C.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-4637","authenticated-orcid":false,"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1096\/fj.06-7924com","article-title":"Cathepsin cysteine proteases in cardiovascular disease","volume":"21","author":"Lutgens","year":"2007","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.09.006_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2018.09.006_bib3","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/rheumatology\/keu486","article-title":"Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies","volume":"54","author":"Weitoft","year":"2015","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s12035-013-8576-6","article-title":"Cysteine cathepsins in neurological disorders","volume":"49","author":"Pislar","year":"2014","journal-title":"Mol. Neurobiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2018.09.006_bib5","doi-asserted-by":"crossref","first-page":"H974","DOI":"10.1152\/ajpheart.00125.2015","article-title":"Cathepsins in heart disease-chewing on the heartache?","volume":"308","author":"Blondelle","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.006_bib6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1210\/jc.2005-1601","article-title":"Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women","volume":"91","author":"Taleb","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.atherosclerosis.2005.08.001","article-title":"Increased serum cathepsin S in patients with atherosclerosis and diabetes","volume":"186","author":"Liu","year":"2006","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1399-0004.2008.01043.x","article-title":"Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations","volume":"74","author":"Spielmann","year":"2008","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jama.2011.1246","article-title":"Association between serum cathepsin S and mortality in older adults","volume":"306","author":"Jobs","year":"2011","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.09.006_bib10","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1096\/fj.201600508R","article-title":"Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity","volume":"30","author":"Dinnes","year":"2016","journal-title":"Faseb. J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib11","first-page":"163","article-title":"The function of cathepsins B, D, and X in atherosclerosis","volume":"6","author":"Zhao","year":"2016","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41512-017-0009-y","article-title":"Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial","volume":"1","author":"Winkel","year":"2017","journal-title":"Diagnostic and Prognostic Research"},{"issue":"7532","key":"10.1016\/j.atherosclerosis.2018.09.006_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.38666.653600.55","article-title":"Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial","volume":"332","author":"Jespersen","year":"2006","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000128994","article-title":"Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease","volume":"111","author":"Gluud","year":"2008","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diagmicrobio.2009.11.011","article-title":"Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial","volume":"66","author":"Hilden","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.09.006_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jac\/dkp190","article-title":"Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial","volume":"64","author":"Jespersen","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib17","first-page":"182","article-title":"Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial","author":"Winkel","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2011.09.011","article-title":"Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease","volume":"65","author":"Kj\u00f8ller","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.12.032","article-title":"Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial","volume":"168","author":"Kj\u00f8ller","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib20","first-page":"118","article-title":"Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?","author":"Winkel","year":"2011","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.09.006_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.imbio.2012.10.015","article-title":"Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial","volume":"218","author":"Harutyunyan","year":"2013","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2018.09.006_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2018.09.006_bib23","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/febs.14043","article-title":"Cysteine proteases in atherosclerosis","volume":"284","author":"Weiss-Sadan","year":"2017","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/STROKEAHA.115.011573","article-title":"Characterizing cathepsin activity and macrophage subtypes in excised human carotid plaques","volume":"47","author":"Abd-Elrahman","year":"2016","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.006_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0019-4832(12)60089-3","article-title":"Levels of cathepsins in acute myocardial infarction","volume":"64","author":"Shalia","year":"2012","journal-title":"Indian Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.09.006_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1515\/bchm3.1986.367.1.39","article-title":"Degradation of myocardial structural proteins in myocardial infarcted dogs is reduced by Ep459, a cysteine proteinase inhibitor","volume":"367","author":"Tsuchida","year":"1986","journal-title":"Biol. Chem. Hoppe Seyler"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.006_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejheart.2005.09.004","article-title":"Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy","volume":"8","author":"Ge","year":"2006","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1309\/AJCPLVQQY35XTFVN","article-title":"Measurement of high-sensitivity troponin T in noncardiac medical intensive care unit patients. Correlation to mortality and length of stay","volume":"141","author":"Baron","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.006_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/00365513.2011.552631","article-title":"Inflammatory response is associated with increased cathepsin B and decreased cathepsin S concentrations in the circulation","volume":"71","author":"\u00c5kerfeldt","year":"2011","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2016.09.062","article-title":"The association between serum cathepsin L and mortality in older adults","volume":"254","author":"Feldreich","year":"2016","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2018.09.006_bib31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1089\/ars.2015.6404","article-title":"Is there any role for serum cathepsin S and CRP levels on prognostic information in breast cancer? The Swedish mammography cohort","volume":"23","author":"Basu","year":"2015","journal-title":"Antioxidants Redox Signal."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.09.006_bib32","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/ijms12031505","article-title":"IL-8 and cathepsin B as melanoma serum biomarkers","volume":"12","author":"Zhang","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.09.006_bib33","first-page":"1511","article-title":"Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer","volume":"4","author":"Kos","year":"1998","journal-title":"Clin. Canc. Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.09.006_bib34","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.10604","article-title":"Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma","volume":"94","author":"Sinha","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.atherosclerosis.2018.09.006_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12885-016-2283-4","article-title":"Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma","volume":"16","author":"Tan","year":"2016","journal-title":"BMC Canc."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.09.006_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.atherosclerosis.2011.02.016","article-title":"Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease","volume":"216","author":"Urbonaviciene","year":"2011","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.09.006_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000381664","article-title":"Endostatin, cathepsin S, and cathepsin L, and their association with inflammatory markers and mortality in patients undergoing hemodialysis","volume":"39","author":"Carlsson","year":"2015","journal-title":"Blood Purif."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018313674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018313674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T22:05:11Z","timestamp":1546639511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018313674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"alternative-id":["S0021915018313674"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.09.006","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}